Maurizio Chiriva-Internati net worth and biography

Maurizio Chiriva-Internati Biography and Net Worth

Dr. Chiriva Internati has served as our Chairman and Chief Executive Officer since February 2018 and as our President since October 2019. Between December 2012 and September 2019, he served as Chief Scientific Officer. Between December 2012 and August 2018, he also served as our Director of Clinical Translation Research. Dr. Chiriva Internati has been an Associate Professor at the MD Anderson Cancer Center in Houston, Texas since August 2019. Prior to that, he served as an Associate Professor at Texas Tech University Health Sciences Center from September 2013 to June 2017. His research has led to the identification of novel cancer-testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. This led to the development of the bioinformatic software Diamond CancerSplice, which is a key core platform of our company, leading to the discovery and prioritization of isoform antigens via insilico system.

Dr. Chiriva Internati earned a PhD in Immunology from the University of Nottingham, United Kingdom. He also earned a PhD in Morphological Science from the Universit`a degli Studi di Milano, Italy, and a Doctoral Degree in Biological Sciences from the University of Milan, Italy. Dr. Chiriva- Internati was a Post-Doctoral Fellow in Immunology at the University of Arkansas for Medical Sciences, earned a certificate in Artificial Intelligence from MIT Sloan School of Management and earned a certificate in Financial Technology from Oxford Sa¨ıd Business School.

What is Maurizio Chiriva-Internati's net worth?: The estimated net worth of Maurizio Chiriva-Internati is at least $119,431.00 as of September 9th, 2021. Dr. Chiriva-Internati owns 45,935 shares of Kiromic BioPharma stock worth more than $119,431 as of April 19th. This net worth estimate does not reflect any other investments that Dr. Chiriva-Internati may own. Learn More about Maurizio Chiriva-Internati's net worth.
How do I contact Maurizio Chiriva-Internati?: The corporate mailing address for Dr. Chiriva-Internati and other Kiromic BioPharma executives is , , . Kiromic BioPharma can also be reached via phone at 832-968-4888 and via email at [email protected]. Learn More on Maurizio Chiriva-Internati's contact information.
Has Maurizio Chiriva-Internati been buying or selling shares of Kiromic BioPharma?: Maurizio Chiriva-Internati has not been actively trading shares of Kiromic BioPharma over the course of the past ninety days. Most recently, on Thursday, September 9th, Internati Maurizio Chiriva bought 93 shares of Kiromic BioPharma stock. The stock was acquired at an average cost of $111.00 per share, with a total value of $10,323.00. Following the completion of the transaction, the chief executive officer now directly owns 45,935 shares of the company's stock, valued at $5,098,785. Learn More on Maurizio Chiriva-Internati's trading history.

Maurizio Chiriva-Internati Insider Trading History at Kiromic BioPharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2021	Buy	93	$111.00	$10,323.00	45,935

Maurizio Chiriva-Internati Buying and Selling Activity at Kiromic BioPharma

Kiromic BioPharma Company Overview

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Today's Range

Now: $2.60

$2.55

$2.60

50 Day Range

MA: $2.63

$1.49

$3.46

2 Week Range

Now: $2.60

$0.16

$8.97

Volume

716 shs

Average Volume

8,544 shs

Market Capitalization

$3.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report